Bioversys reported a wider first-half loss on Wednesday but said it remains funded through 2028, while also lowering its full-year operating-loss outlook.
The Basel-based company, whose entire pipeline remains in pre-commercial research, posted operating income of CHF 2 million in H1 2026, up CHF 1.4 million from the same period a year earlier. The increase included revenue for the first time from a research cooperation with Japanese pharmaceutical group Shionogi, concluded last year.
Total costs came to CHF 16.6 million, of which CHF 13.6 million was allocated to research and development. That produced an operating loss of CHF 14.6 million, compared with CHF 9.4 million a year earlier. The net loss widened by CHF 4.6 million to CHF 15.6 million.
Cash and equivalents stood at CHF 69.3 million as of mid-2026, down from CHF 82.5 million at the end of 2025.
For the full year, Bioversys now expects an operating loss of CHF 32 million to CHF 34 million, revising down from its previous forecast of CHF 40 million to CHF 45 million. Cash at year-end is projected to be approximately CHF 53 million.
On the clinical front, the company said its global Phase III trial RIV-TARGET for antibiotic candidate BV100 launched in April and will enroll roughly 300 patients. Topline data are expected in early 2028. An additional Phase IIb study with BV100 is slated to begin at initial sites in September.
Separately, tuberculosis candidate Alpibectir, co-developed with GlaxoSmithKline, saw its first patient treated in a Phase IIb/c study in March. A further Phase II trial targeting tuberculous meningitis is expected to enrol its first patient in the fourth quarter.
